IRIS
GIANNINI, EDOARDO GIOVANNI BATTISTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 28.728
Totale 28.728
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 28.728
Totale 28.728
Salva come PNG Salva come JPEG
Città #
Genova 21.585
Rapallo 3.046
Genoa 2.540
Vado Ligure 1.487
Bordighera 70
Totale 28.728
Salva come PNG Salva come JPEG
Nome #
Hepatobiliary and Pancreatic: A rare cause of portal hypertension. 173
Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C 159
Epidemiological and clinical features of hepatitis delta in HBsAg-positive patients by HIV status. 158
5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for “best evidence”? 154
Positive PET in a patient with esophageal leiomyoma. 148
A new assay for hepatitis C virus (HCV) core antigen detection: an alternative to nucleic acid technologies in positive or indeterminate anti-HCV subjects? 147
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. 147
13C -Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. 146
Personalized treatment of patients with very early hepatocellular carcinoma 145
Long-Term Follow-Up Study of Liver-Related Outcome After Bilio-Pancreatic Diversion in Patients with Initial, Significant Liver Damage 145
13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease 142
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. 141
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 140
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy 138
PRO: Cirrhotic patients with small esophageal varices should undergo primary prophylaxis 136
IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin. 136
Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease 132
Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. 131
Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis 130
Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma 129
Breath tests to assess alcoholic liver disease. 129
Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis 129
Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. 128
Hepatocellular carcinoma in patients with cryptogenic cirrhosis 128
A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice 128
A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. 128
A study of 4-and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication 128
Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma 127
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 127
Acquired Hepatocerebral Degeneration in the Absence of Portosystemic Shunting 127
External Validation of the Platelet Count/Spleen Diameter Ratio for the Diagnosis of Esophageal Varices in Hepatitis C Virus-Related Cirrhosis 126
Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. 126
Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. 125
Blessed are those who have not seen and yet have believed 125
Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease 125
MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study 124
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 124
Is there a role for multiple quantitative liver function tests? 123
Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis? 123
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. 123
Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: a validation study based on follow-up 122
Effects of reduced glutathione and n-acetylcysteine on lidocaine metabolism in cimetidine treated rats 122
A summary of the 6th international conference on coagulation in liver disease: Discussion, debate, deliberations 122
Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. 121
Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C 121
Adalimumab trough levels and response to biological treatment in patients with Inflammatory Bowel Disease: a useful cut-off In clinical practice. 121
The monoethylglycinexylidide test does not impair psychometric performance in patients with chronic hepatitis or cirrhosis 120
A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients 120
Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems 119
Feasibility of the cut-and-push method for removing large caliber, soft, percutaneous endoscopic gastrostomy devices. 119
Leptin in nonalcoholic steatohepatitis: is it one of the "hits"? 119
Platelet dysfunction: status of thrombopoietin in thrombocytopenia associated with chronic liver failure 118
An independent validation of the mortality score for the short-term prognostic prediction in patients with chronic hepatitis C virus infection and advanced liver disease 118
Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. 118
High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease 118
Starry Liver: An Unexpected Diagnosis 117
Reply to Farinati et al.: classification of 'intermediate stage', untreated hepatocellular carcinoma patients: the neighbour's grass is not so green 116
Alpha-fetoprotein in hepatocellular carcinoma surveillance: wake not the dead. 116
Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn’s disease. 116
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 116
Chronic hepatitis C in different populations: similar patterns of alanine aminotransferase alteration characterize similar clinical subgroups. 115
Persistently normal aminotransferase in chronic hepatitis C virus infection: is it time to redefine parameters of "normality"? 115
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens 115
Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study. 115
Eltrombopag in patients with chronic liver disease. 115
Significance of platelet and AFP levels and liver function parameters for HCC size and survival. 115
Hepatocellular carcinoma in patients without cirrhosis in Italy. 114
Liver enzyme alteration: a guide for clinicians 114
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 114
Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy? 113
Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria 113
Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? 112
Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. 112
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 112
Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients 112
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. 112
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 112
Curative therapies are superior to standard of care(transarterial chemoembolization)for intermediate stage hepatocellular carcinoma 112
Is aspartate aminotransferase enough? 111
Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease 111
12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies. 111
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: characteristics and outcome of antiviral therapy. 110
Predictive factors for response to Peginterferon-Alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more 110
Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn 110
Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters. 110
. Liver iron accumulation in chronic hepatittis C patients without HFE mutations: relationships with histological damage, viral load and genotype, and alpha glutathione S-transferase levels. 109
Application of the intermediate stage sub-classification to patients with untreated hepatocellular carcinoma 109
A Nodule, is a Nodule, is a Nodule: May Alpha-fetoprotein Make the Difference? 109
The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin 109
Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study. 108
HEMOSTATIC BALANCE IN PATIENTS WITH LIVER CIRRHOSIS: Report of a Consensus Conference 108
Eltrombopag in patients with chronic hepatitis C and thrombocytopenia. 108
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 108
Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden 107
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia 107
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. 107
Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study 107
Editorial: a step forward in refining prognostication for patients with HIV-associated hepatocellular carcinoma 107
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice 107
Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN) 107
Totale 12.211
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.916
article - articoli 98.742
book - libri 0
conference - conferenze 193
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 981
Totale 199.832
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.679 0 0 0 0 759 866 1.190 585 822 1.368 761 328
2020/20212.763 142 288 229 204 181 279 119 279 228 312 226 276
2021/20224.035 174 266 310 354 126 252 239 997 267 360 209 481
2022/20233.705 384 228 37 284 603 614 34 361 685 21 391 63
2023/20241.986 95 277 40 238 171 229 128 120 116 74 153 345
2024/20251.665 232 483 229 382 339 0 0 0 0 0 0 0
Totale 29.695